This week brought significant updates in the pharmaceutical and biotech sectors, including safety concerns in CAR-T therapies, a setback for Ultragenyx, a major licensing deal in China, progress on an mRNA flu vaccine, and new agreements under the Most Favored Nation (MFN) program.
CAR-T Trials on Hold: Safety Concerns Arise
Recent safety incidents have led both Novartis and Bristol Myers Squibb to pause several trials of their CAR-T cell therapies targeting autoimmune diseases. Novartis halted eight studies involving Rap-cel due to three cases of a serious reaction known as immune effector cell-associated hemophagocytic syndrome (IEC-HS), which resulted in fatalities. Similarly, Bristol Myers took the precaution of pausing enrollment in trials for zolacabtagene autoleucel (Zola-cel) after observing reversible inflammatory events, although it continued the studies.
While the safety events reported by Novartis and Bristol Myers are related to CAR-T therapies, they differ significantly in severity and implications. Novartis’s findings prompted a thorough review as they indicated fatal outcomes, while Bristol Myers has characterized its cases as less severe and reversible.
Manufacturing Speed Under Scrutiny
Analysts suggest that the rapid production methods used for both therapies could be linked to these safety issues. Novartis’s approach aims for faster cell expansion, which some believe might lead to increased toxicity. This situation has raised concerns across the broader autoimmune CAR-T landscape, particularly given the scale of Novartis’s trial suspensions. Companies like Kyverna Therapeutics and Cabaletta Bio are now under scrutiny as investors speculate on whether the observed safety signals are specific to certain manufacturing processes or indicative of a more widespread concern.
Ultragenyx Faces Setback with Angelman Syndrome Treatment
Ultragenyx Biotechnology experienced a steep decline in its stock price after its treatment apazunersen failed to meet key endpoints in the Phase 3 Aspire trial for Angelman syndrome. This trial aimed to assess improvements in cognitive and nonverbal reasoning skills but found no substantial difference between the treatment and placebo groups. This is not the first setback for Ultragenyx, marking its second consecutive late-stage trial failure, which analysts view as detrimental to investor confidence.
The future of the Angelman program is now uncertain as the company evaluates next steps. Despite this setback, Ultragenyx had a recent success with its gene therapy Genglycos, which received FDA approval for treating Von Gierke disease, providing a glimmer of hope amidst challenges.
Simcere Zaiming and Roche: A Major Licensing Deal
In a significant move, Roche has secured exclusive global rights to develop SIM0660, a tri-specific antibody created by Simcere Zaiming. This innovative therapy targets two B-cell antigens, CD79a and CD19, alongside a CD3-engaging arm, enhancing T-cell-mediated cytotoxicity while minimizing cytokine release. The deal, valued at up to $1.53 billion, highlights the growing interest in novel therapeutic approaches from China.
Simcere’s strategy reflects a broader trend where innovative Chinese biotechnology firms are gaining recognition on the global stage, indicating a shift in how new drug modalities are developed and commercialized.
GSK’s mRNA Flu Vaccine Progresses to Phase III
GSK is making strides with its mRNA flu vaccine candidate, FLUm3HA.b-3NA, advancing to a Phase III efficacy trial. This decision follows encouraging Phase II results showing superior immune responses compared to existing flu vaccines. GSK’s vaccine distinguishes itself by targeting both hemagglutinin and neuraminidase, which may enhance protection against influenza.
The ongoing Phase III trial will be crucial as it tests this dual-targeting approach, potentially offering better outcomes than traditional vaccines, particularly in terms of reducing illness severity and transmission.
Expansion of the MFN Program
The Most Favored Nation (MFN) program has expanded, with nine additional companies joining the initiative. This program aims to lower drug prices and now encompasses a total of 26 signatories, covering a significant portion of the branded drug market. The new agreements not only focus on pricing but also commit these companies to invest in U.S. manufacturing, enhancing domestic production capabilities.
While the MFN agreements might not directly impact out-of-pocket costs for patients, they signal a broader shift in how pharmaceutical companies are engaging with pricing and production strategies in the U.S. market.
Lilly Acquires Merida Biosciences
Lilly has announced its acquisition of Merida Biosciences for up to $2.875 billion. Merida specializes in biologics designed to selectively degrade pathogenic autoantibodies, which are implicated in various immune-mediated diseases. This acquisition aligns with Lilly’s ongoing commitment to precision immunology and its strategy to develop targeted therapies that address the underlying causes of these conditions.
Through this acquisition, Lilly aims to bolster its portfolio with innovative treatments that could transform the management of autoimmune diseases.
Conclusion
This week’s developments reflect a dynamic landscape in the pharmaceutical and biotech industries, marked by both significant challenges and promising advancements. As companies navigate safety concerns, trial setbacks, and new collaborations, the focus remains on innovation and strategic growth in an ever-evolving market.
- Bristol Myers and Novartis halt CAR-T trials due to safety concerns.
- Ultragenyx faces a setback with its Angelman syndrome treatment.
- Roche’s licensing deal for SIM0660 highlights the rise of Chinese biotech.
- GSK progresses its mRNA flu vaccine toward Phase III trials.
- MFN program expands to include nine additional pharmaceutical companies.
Read more → www.pharmexec.com
